Elevai Labs Inc amended its Series B Preferred Stock rights on February 21, 2025, clarifying that holders have no conversion rights and are not entitled to dividends unless declared by the Board; additionally, on February 24, 2025, the authorized shares of Series B Preferred Stock were increased from 50 million to 300 million.